The Newfangled Obesity Drug Story

The drug makers making GLP1 drugs have been trying to see if they could be helpful with fatty liver disease or NASH. Novo has conducted trials testing some aglitide in NASH. They have so far not yet shown to improve liver-starring or fibrosis. But there's more and more evidence behind targeting glucagon specifically as a helpful mechanism for fatty liver disease.